McDermott Will & Emery LLP
Roger Kuan focuses his practice on intellectual property (IP) procurement/portfolio management, IP transactions IP litigation and strategic IP counseling for life sciences clients (e.g., research tools, analytical instrumentation/software, medical devices, diagnostics, biomanufacturing systems, etc.) with a focus in emerging technologies such as digital health (e.g., mobile apps, clinical decision support software, digital therapeutics, AI/ML imaging diagnostics, etc.), personalized medicine (e.g., genomic sequencing platforms, AI/ML computational genomics/bioinformatics, molecular diagnostics, etc.) and 3D printing/bioprinting. He has extensive experience in intellectual property strategy and management, preparation and prosecution (utility/design patents, trademarks and trade dress), counseling and litigation, licensing and technology transactions, freedom-to-operate clearances, monetization, IP due diligence, IP risk recognition and mitigation, and dispute resolution. He served as Director IP Counsel at a multinational biotechnology company, where he managed a team to support the worldwide IP needs of the company’s life sciences tools, bioproduction/biomanufacturing, molecular diagnostics, and nucleic acid sequencing system/software platforms. Prior to finishing his law degree, Roger worked in the life sciences industry for several Fortune 500 pharmaceutical, medical device, and chemical companies. He has held professional positions in the R&D, sales, engineering, and regulatory affairs organizations.